Monitor FDA review timeline (typically 10-12 months from acceptance) and any AdCom vote. Approval of AVT16 would add a second interchangeable biosimilar to Alvotech's U.S. portfolio and could generate meaningful revenue via Teva partnership. The February 2026 AVT80 PK data is a positive cross-supporting signal.
Price Chart
Executive Summary
Alvotech announced FDA acceptance of its BLA for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for IV use in ulcerative colitis and Crohn's disease. This is a procedural milestone—acceptance for review does not guarantee approval—but it advances a key pipeline asset partnered with Teva. The filing also notes positive Phase 1 data for AVT80 (subcutaneous Entyvio biosimilar) from February 2026, which supports both candidates.
Key Facts
- FDA accepted for review the BLA for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for IV administration.
- Alvotech is responsible for development and manufacturing; Teva is responsible for commercialization in the U.S.
- AVT16 targets moderately to severely active ulcerative colitis and Crohn's disease in adults.
- In February 2026, Alvotech reported positive pivotal PK study results for AVT80 (subcutaneous Entyvio biosimilar), which also supports AVT16's clinical similarity package.
- AVT16 and AVT80 are investigational and have not received regulatory approval in any market.
- Alvotech has five approved biosimilars on the market and a pipeline of nine disclosed candidates.
Financial Impact
No financial terms disclosed; BLA acceptance is procedural with no immediate revenue impact. Entyvio had U.S. sales of approximately $5.5B in 2025 (not stated in filing, for context only).
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on safety, efficacy, or CMC grounds, delaying or denying approval.
- Entyvio faces competition from other biosimilars (e.g., Celltrion, Samsung Bioepis) that could erode market opportunity.
- Interchangeability designation is not guaranteed and requires additional data; without it, market uptake may be slower.
- Alvotech has a history of FDA manufacturing deficiencies (not stated in filing, but known from prior context).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307832 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $5.12 | awaiting T+20 | — | $4.62 (−9.77%) |
Oct 14, 2026 12d ago | 6-K | $5.17 | awaiting T+20 | — | $4.62 (−10.64%) |
Oct 7, 2026 19d ago | 6-K | $5.85 | awaiting T+20 | — | $4.62 (−21.03%) |
Oct 5, 2026 21d ago | 6-K | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Oct 5, 2026 22d ago | Press Release | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.62 (−10.98%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.62 (+4.29%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.62 (−8.20%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.62 (+30.88%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.62 (+33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers